BioSpace News Archive

Cognito Therapeutics and Aetion announced a strategic partnership to develop a validated predictive model to identify patients with rapidly progressing mild cognitive impairment and Alzheimer’s disease.

Mytide Therapeutics, a company transforming peptide manufacturing with predictive analytics and machine learning, has raised $7 million in Series A financing.

Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, announced the appointment of Nancy Beesley to its Board of Directors.

“Caraway is developing oral small molecule therapeutics that enhance lysosomal function to accelerate clearance of toxic materials, such as proteins, oligomers and lipids, that accumulate in many genetically defined neurodegenerative and rare diseases,” said Williams.

Fabric Genomics, Inc., announced that the Broad Institute of MIT and Harvard has selected the company to support the development and implementation of its clinical whole genome sequencing-based offerings.

Australian clinical-stage drug development company Noxopharm has announced its Phase 1 CEP-2 sarcoma trial is underway with a first patient enrolled and dosed at City of Hope in Los Angeles, California.

Cortexyme, Inc. announced results from the single ascending dose portion of the Phase 1 clinical trial of its new drug candidate COR588, a next generation, oral, small-molecule lysine gingipain inhibitor in development for the treatment of diseases related to P. gingivalis infection.

Inscopix, Inc. announced that it has launched a new application for its miniscope-based platforms to investigate neuronal activity and blood flow simultaneously, a novel research method that may prove critical to studying neurovascular dynamics in the context of aging, dementia, stroke and other debilitating diseases.

PhaseBio Pharmaceuticals, Inc oday announced the completion of the bentracimab drug substance and drug product Process Performance Qualification (PPQ) campaign.

Sharp HealthCare, in collaboration with Nascent Biotech, Inc, announced today, its participation in a clinical trial for a novel investigational immunotherapy treatment for patients with glioblastoma (GBM), the deadliest form of brain cancer.